Log in
NASDAQ:TROV

TrovaGene Stock Forecast, Price & News

$10.71
-0.64 (-5.64 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.21
Now: $10.71
$11.24
50-Day Range
$1.19
MA: $6.78
$11.60
52-Week Range
$0.70
Now: $10.71
$3.46
Volume1.04 million shs
Average Volume648,892 shs
Market Capitalization$117.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Read More
TrovaGene logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TROV
CUSIPN/A
Phone858-952-7570

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$0.94 per share

Profitability

Net Income$-16,410,000.00
Net Margins-3,688.31%

Miscellaneous

EmployeesN/A
Market Cap$117.93 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$10.71
-0.64 (-5.64 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TrovaGene (NASDAQ:TROV) Frequently Asked Questions

How has TrovaGene's stock been impacted by COVID-19 (Coronavirus)?

TrovaGene's stock was trading at $1.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TROV shares have increased by 864.9% and is now trading at $10.71.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of TrovaGene?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TrovaGene
.

When is TrovaGene's next earnings date?

TrovaGene is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for TrovaGene
.

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) issued its earnings results on Thursday, February, 27th. The medical research company reported ($0.51) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. TrovaGene had a negative net margin of 3,688.31% and a negative return on equity of 202.00%.
View TrovaGene's earnings history
.

When did TrovaGene's stock split? How did TrovaGene's stock split work?

TrovaGene's stock reverse split before market open on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for TROV?

2 brokers have issued 1 year target prices for TrovaGene's stock. Their forecasts range from $6.00 to $23.00. On average, they expect TrovaGene's stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 35.4% from the stock's current price.
View analysts' price targets for TrovaGene
.

Who are some of TrovaGene's key competitors?

What other stocks do shareholders of TrovaGene own?

Who are TrovaGene's key executives?

TrovaGene's management team includes the following people:
  • Dr. Thomas H. Adams, CEO & Exec. Chairman (Age 76)
  • Dr. Mark Erlander, Chief Scientific Officer (Age 59)
  • Ms. Elizabeth Anderson, VP of Fin. & Admin.
  • Mr. George Samuel, VP & Gen. Counsel
  • Ms. Vicki Kelemen, VP of Corp. Communications

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

How do I buy shares of TrovaGene?

Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TrovaGene's stock price today?

One share of TROV stock can currently be purchased for approximately $10.71.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $117.93 million and generates $250,000.00 in revenue each year. The medical research company earns $-16,410,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

What is TrovaGene's official website?

The official website for TrovaGene is www.trovagene.com.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.